Human embryonic stem cells (hESCs) provide a novel source of hematopoietic and other cell populations suitable for gene therapy applications. Preclinical studies to evaluate engraftment of hESC-derived hematopoietic cells transplanted into immunodeficient mice demonstrate only limited repopulation. Expression of a drug-resistance gene, such as Tyr22-dihydrofolate reductase (Tyr22-DHFR), coupled to methotrexate (MTX) chemotherapy has the potential to selectively increase the engraftment of gene-modified, hESC-derived cells in mouse xenografts. Here, we describe the generation of Tyr22-DHFR-GFP-expressing hESCs that maintain pluripotency, produce teratomas and can differenti-ate into MTXr-hemato-endothelial cells. We demonstrate that MTX administered to nonobese diabetic/severe combined immunodeficient/IL-2Rgc null (NSG) mice after injection of Tyr22-DHFR-hESC-derived cells significantly increases human CD34 + and CD45 + cell engraftment in the bone marrow (BM) and peripheral blood of transplanted MTXtreated mice. These results demonstrate that MTX treatment supports selective, long-term engraftment of Tyr22-DHFR cells in vivo, and provides a novel approach for combined human cell and gene therapy.
Introduction
Over the past two decades, development of stem-cellbased gene therapies has been challenging due to low level of gene transfer in human hematopoietic stem cells (HSCs) and difficulties with long-term stable engraftment of modified cells. 1 In clinical trials for X-linked severe combined immunodeficiency (X-SCID) and adenosine deaminase deficiency (ADA-SCID), the growth advantage of gene-modified lymphocytes compensated for the low level of gene transfer to support immune reconstitution. [2] [3] [4] [5] However, in cases where the gene of interest does not confer a selective advantage to modified cells, expression of drug-resistance gene in HSCs may be clinically beneficial. For example, drug-resistance-gene expression coupled to chemotherapy has been shown to selectively expand gene-modified cells in vivo. [6] [7] [8] In addition, drug-resistance-gene expression in non-malignant, chemosensitive tissues, such as the bone marrow (BM) and gastrointestinal tract, has the potential to decrease toxicity associated with high-dose chemo-therapy. 7 In the allogeneic setting, coupling post-transplantation immunosuppressive drug treatment to drug resistance in the allograft also has the potential to reduce the risk of graft rejection and the severity of graft-versushost disease.
Methotrexate (MTX) is widely used in post-HSC transplantation immunosuppressive therapy and in treatment of some cancers. [9] [10] [11] We and others have shown that gene transfer and expression of an MTXresistant (MTXr) dihydrofolate reductase (Tyr22-dihydrofolate reductase (Tyr22-DHFR)) in HSCs confers chemoprotection to recipient animals. [12] [13] [14] In these studies, MTX supported a transient, drug-dependent, selective expansion of gene-modified cells in the peripheral blood of treated animals. These results suggest that MTX administration may be used to regulate in vivo expansion of gene-modified cells.
Human embryonic stem cells (hESCs) are capable of self-renewal and can be induced to differentiate into diverse hematopoietic cell lineages, including myeloid and lymphoid lineages of characteristic phenotypes and function. [15] [16] [17] [18] [19] [20] We have also found that natural killer cells derived from hESCs have potent antitumor activity both in vitro and in vivo. 21, 22 Others have characterized maturation of erythroid cells from hESCs with normal oxygen-carrying capacity. [23] [24] [25] However, in studies to date, only limited long-term hematopoietic potential of hESC-derived cells has been observed when transplanted into immunodeficient mice or in fetal sheep models. [26] [27] [28] [29] Several studies have focused on gene modification of hESCs, defining optimal conditions for achieving stable viral and non-viral transfer of genes encoding bioluminescent or fluorescent proteins. [30] [31] [32] Other groups have demonstrated the expression of antibiotic-resistance genes for enrichment of drug-resistant cells, [33] [34] [35] or used lineage-or stage-specific regulation of green fluorescent protein (GFP) to monitor differentiation of hESCs. [36] [37] [38] [39] To date, gene transfer and in vivo expression of chemotherapeutic drug-resistance genes, such as Tyr22-DHFR, in hESC-derived cells has not been reported.
Clinically, Tyr22-DHFR expression by hematopoietic progenitor cells derived from either hESCs or induced pluripotent stem cells coupled to MTX chemotherapy after HSC transplantation could potentially protect the transplanted cells, providing selective engraftment advantage to improve levels of long-term engraftment. Here, we describe stable expression of Tyr22-DHFR and GFP in hESCs after lentiviral transduction. These Tyr22-DHFR-GFP cells were evaluated in vitro and in vivo to demonstrate improved cell survival, maintaining hematopoietic differentiation potential while under MTX selection when transplanted into immunodeficient mice.
Results

Stable expression of DHFR and GFP in undifferentiated hESCs
In order to determine the vector design that would best support long-term DHFR and GFP expression in hESCs, the human H9 cell line was transduced with three different bifunctional self-inactivating lentiviral vectors, each containing the human elongation factor-1-a (hEF1-a) promoter regulating transcription of the murine Tyr22-DHFR variant (Figure 1a ). Other genetic features include a posttranscriptional regulatory element (pre), rev response element (rre) and a central polypurine tract. In the EFDIG lentiviral vector, the DHFR-and GFPcoding sequences are separated by an internal ribosomal entry site for translation of both proteins from one transcribed message. We also engineered a vector (DL2G) expressing a DHFR-GFP fusion protein with the intent that GFP expression would more accurately reflect drug resistance in transduced cells. Our previous transduction studies with mouse HSCs showed that EFDIG conferred a higher level of chemoprotection in vivo, compared with DL2G. 12 We also evaluated a two-promoter configuration (REDPeG), because our recent studies using canine HSCs have shown that this vector supports a higher level of GFP expression as compared with EFDIG and DL2G, thus providing easier detection of gene-modified cells in vivo (unpublished observation). Also included in all studies is a GFP-only control (CSIIEG), which has also been previously described. 40 All studies here were conducted with the H9 hESC line that has been commonly used for studies to derive hematopoietic and other cell lineages. This line is quite amenable to stable genetic modification while retaining a normal karyotype and pluripotency. 31 Four days after transduction (as detailed under Materials and methods), characteristic colonies emerged, some of which were GFP + when evaluated by fluorescence microscopy. The GFP + colonies transduced with the vectors described above retained the characteristic hESC morphology, and GFP expression was distributed evenly among the cells in each colony ( Figure 1b ). One month after transduction, the cells maintained the morphology of undifferentiated hESCs and 40-80% of the transduced populations were positive for both GFP and stage-specific embryonic antigen-4 (SSEA-4), indicating stable transgene expression in undifferentiated cells (Figure 1c ). All gene-modified cell populations retained a normal karyotype ( Supplementary Figure 1 ). While fluorescence intensity was highest for CSIIEG-hESCs and DL2G-hESCs, and lower for EFDIG-hESCs and REDPeG-hESCs, all gene-modified populations contained 1-2 vector copies per genome equivalent as determined by quantitative PCR. Since GFP expression was similar in EFDIG and DL2G cell populations (B60% GFP + cells), we also determined MTXr-DHFR enzyme activities in cell extracts. In the absence of MTX, there was no significant difference in DHFR activities among the different transduced cell populations (Table 1) . However, in the presence of MTX, DHFR activity was significantly higher in extracts from EFDIG-H9 (Po0.005) and DL2G-H9 (Po0.01) populations as compared with that from CSIIEG-H9 (GFP only control) extracts in which MTXr-DHFR activity was undetectable. Interestingly, DHFR activity was not significantly increased by Tyr22-DHFR expression in the absence of MTX. Given the higher level of enzyme activity associated with EFDIG-hESCs and our previous studies showing that EFDIG confers a higher level of chemoprotection in mice as compared with DL2G, 12 we selected the EFDIG-modified hESCs for subsequent in vivo studies.
MTX dose escalation and teratoma formation in immunodeficient mice
Previous studies using immunocompetent mice showed that transplantation with marrow that expresses MTXr-DHFR (MTXr-DHFR marrow) protects recipients from chemotoxicity. 12 In preparation for long-term MTX treatment of immunodeficient mice, we first transplanted nonobese diabetic (NOD).Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice with MTXr-DHFR or GFP lentivirus-transduced BM as described under Materials and methods. MTX was administered daily by intraperitoneal route, starting at 0.25 mg kg À1 day À1 . The dose was increased if both animal weight and hematocrit were stable among the mice in a particular cohort (Supplementary Figure 2) . The goal of this dose escalation experiment was to determine the maximum MTX dose that could be tolerated by DHFR-transduced BM transplanted (BMT) NSG mice without causing anemia. We found that mice transplanted with GFP-transduced marrow could tolerate up to 0.5 mg kg À1 day À1 , whereas DHFR-transduced BMT mice tolerated up to 2 mg kg À1 day À1 while maintaining stable health and hematocrits (Supplementary Figure 2 ).
Using these mice engrafted with MTXr marrow, we next evaluated the ability of EFDIG-hESCs to give rise to advanced derivatives of all three germ layers in teratomas that were allowed to develop in the presence and absence of MTX. In this assay, EFDIG-and CSIIEGundifferentiated hESCs were injected into the left and right hind limbs of DHFR-chemoprotected NSG mice, respectively. One month after hESC injection, animals Expression of MTXr-DHFR in hESCs JL Gori et al were treated daily with either phosphate-buffered saline (PBS) or MTX for 1 month and tumor growth was monitored. Both gene-modified hESC populations gave rise to teratomas. There was a trend toward growth inhibition of CSIIEG teratomas (with no DHFR expression) as compared with growth of EFDIG teratomas (that express DHFR), as would be expected by expression of DHFR, although the difference between these groups was not statistically significant ( Figure 2a ). Notably, in this study, MTX treatment and tumor growth were terminated when tumor size was 1.5 cm, approximately 1 month after the start of MTX treatment. Therefore, this difference in teratoma growth between the treatment groups would likely have been greater if tumors were allowed to grow beyond 1.5 cm (as limited by our animal protocol). Real-time quantitative PCR (qPCR) analysis showed that lentiviral integrants per genome equivalent were maintained or increased slightly during differentiation, compared with GFP marking by qPCR in the input undifferentiated ESC populations (Figure 2a ). Derivatives of all three germ layers and GFP + cells were detected in the teratomas, with no discernible Figure 1 GFP expression in DHFR-GFP-transduced hESCs. (a) DHFR-GFP lentiviral vector schematics. The human EF1-a promoter regulates transcription of Tyr22-DHFR and/or GFP, along with an IRES between the two coding sequences (EFDIG) or as a genetic fusion (DL2G). In a two-promoter configuration (REDPeG), EF1-a regulates Tyr22-DHFR and the human PGK promoter regulates GFP expression. Other features (described under Materials and methods) include the HIV-1R, U5, self-inactivating U3, and rev response element (rre) and the post-transcriptional regulatory element from the Woodchuck hepatitis virus ([w2]wpre). (b) GFP expression was evaluated by fluorescence microscopy of the lentivirus-transduced hESC line H9 4 days after transduction. All images ( Â 10-Â 20 objective) were captured at the same exposure time and modified identically with Adobe Photoshop CS2 version 9 (brightness altered to À60, contrast +35 then applied smart sharpen). (c) Flow cytometric evaluation of GFP expression at 4 weeks. Transduced cells were stained with phycoerythrin-conjugated anti-SSEA-4 to assess the coexpression of GFP and surface expression of SSEA-4 as a marker for undifferentiated hESCs. DHFR, dihydrofolate reductase; EF, elongation factor; GFP, green fluorescent protein; hESC, human embryonic stem cell; IRES, internal ribosome entry site; PGK, phosphoglycerate kinase; SSEA, stage-specific embryonic antigen.
Expression of MTXr-DHFR in hESCs
JL Gori et al developmental differences among treatment groups (Figures 2b and c) . These data indicate that the genemodified hESC maintained their multipotency and gene expression during MTX administration.
DHFR and GFP expression during hESC differentiation on M210 stromal cells
We next compared GFP expression and hematopoietic differentiation in gene-modified hESCs. Here, the four hESC lines transduced with CSIIEG, EFDIG, DL2G or REDPeG were allowed to differentiate by co-culture with M2-10B4 stromal cells as previously described. 17, 41 The level of GFP expression was maintained in CSIIEG cells during this process, but was progressively reduced in DHFR-GFP populations during the 5-week time course Table 1 MTXr-Tyr22DHFR enzyme activity in DHFR-GFP hESC extracts
12 ± 8 0.988 13 ± 7 0.007 CSIIEG-H9 12 ± 2 0 a Cell lysates from transduced or untransduced H9 cells were assayed for DHFR activity in the presence and absence of 0.25 mM MTX. One unit of enzyme activity is defined as 1 nmol/min. Results shown are the mean of three assays ± s.d. b Enzyme activity in extracts from EFDIG-H9 cells and DL2G-H9 cells were compared to CSIIEG-H9 cells using an unpaired, twotailed student's t-test. Figure 3a ). Peak development of CD34 + cells ranged between 10 and 33% (Figure 3b) , similar to what we have previously found for unmodified hESCs. 42 Subpopulations of all transduced differentiated cells also expressed endothelial progenitor markers (ACE, CD31, Flk1) ( Figure 3c and data not shown), also as previously shown for unmodified hESCs. 42, 43 By day 21, subpopulations emerged that coexpressed CD34 and the panhematopoietic marker CD45 (Figure 3d ). Peak expression of CD45 ranged from 1% (EFDIG) to 6% (REDPeG). Importantly, subpopulations of CD34 + were also GFP + (Figure 3e ). Of the DHFR-GFP-transduced cell populations evaluated, coexpression of CD34 and GFP was the highest for EFDIG-transduced cells.
To further define hematopoietic potential and MTX resistance in DHFR + hESC-derived progeny, the cell populations were evaluated for hematopoietic colonyforming cells (CFCs) in the presence of MTX. The Expression of MTXr-DHFR in hESCs JL Gori et al nucleoside transport inhibitor dipyridamole (DP) was included with MTX to provide more stringent selective conditions. 44 As previously demonstrated with other hESC populations, here we found that the gene-modified hESCs readily generate hematopoietic progenitor cells capable of hematopoietic colony formation as quantified in this CFC assay. Importantly and as expected, MTX treatment alone did not inhibit colony formation by CSIIEG-transduced cells (Figure 4a ). However, in the presence of both MTX and DP, CFCs were maintained for all Tyr22-DHFR-transduced cells and significantly reduced for CSIIEG-transduced cells (Figure 4 ). Hemato-poietic cells within the colonies retained GFP expression ( Figure 4b ). These data demonstrate that CFCs derived from hESCs that express Tyr22-DHFR have a survival advantage over control CSIIEG-transduced cells when both folate metabolism and nucleoside transport are inhibited (MTX/DP conditions).
Engraftment and differentiation of DHFR-GFPtransduced hESC hematopoietic progenitors after transplantation into NOD/SCID/IL 2R gc null mice
To further assess the effects of MTX administration and MTXr-DHFR expression by hESC-derived cells in vivo, NSG mice were injected intravenously with 4 Â 10 6 EFDIG-hESC-derived cells after hematopoietic differentiation via M2-10B4 stromal cell co-culture for 10 days. This study consisted of three experimental groups: PBStreated mice (PBS, n ¼ 6), low-dose (0.5 mg kg À1 ) MTXtreated mice (LDM, n ¼ 6) and DHFR marrow transplant recipients treated with high-dose (2 mg kg À1 ) MTX (HDM, n ¼ 8). Mice were treated 5 days per week for 4 weeks with either PBS or MTX. Two weeks after treatment cessation (6 weeks post transplantation), levels of GFP + cells and TRA-1-85 + cells (a monoclonal antibody that recognizes a cell-surface antigen expressed by all human cells) in the blood of HDM and LDM-treated mice were significantly higher than that observed in PBStreated animals (Figure 5a ). Twelve weeks after EFDIG-hESC hematopoietic cell transplantation, GFP + TRA-1-85 + cell levels remained significantly higher in HDM-treated mice, as compared with PBS-treated mice (Figure 5b ). CD34 + and CD45 + cells were also detected in some peripheral blood samples, although at low levels (o1%) (data not shown). Twelve to 16 weeks after EFDIG-cell transplantation, animals were euthanized to evaluate engraftment in different organs. Cells collected from BM, liver and spleen were stained with combinations of antibodies specific for hematopoietic and endothelial lineages. Significantly more GFP + cells were detected in the BM of HDM mice in comparison with LDM or PBS-treated mice (Po0.05; Figure 6a ). QPCR analysis of BM samples confirmed the GFP marking observed by flow cytometry with significantly higher GFP marking observed in LDMand HDM-treated mice as compared with PBS-treated controls (Po0.05). When GFP levels were normalized to the total percentage of GFP marking in the hESC-derived cells at the time of injection (20% GFP + hESC-derived cells at day 10 of differentiation), the difference in GFP marking among treatment groups became more striking ( Figures 5 and 6a ). There was significantly more TRA-1-85 + human cell engraftment in the BM of mice of both MTX treatment groups as compared with PBS-administered mice (Po0.0005), with both CD34 and CD45 subsets represented at significantly higher levels in MTX-treated groups (CD45: Po0.05) ( Figure 6 ). LDMtreated mice exhibited significantly higher CD34 + cell engraftment as compared with both PBS-(Po0.05) and HDM (Po0.005)-administered mice, the latter perhaps resulting from high-dose toxicity for both transduced as well as untransduced cells. Gene-modified human cells were also detected in the spleens and livers of transplanted mice (Figures 6b and c) . We conclude that MTX administration brought about the selective engraftment Figure 4 MTXr-hematopoietic CFC from hESC-derived hematopoietic progenitors. hESCs were induced to differentiate by coculture with M2-10B4 stromal cells. At day 18 of co-culture, populations were evaluated for CFC using no drug (À/À), 30 nM MTX (+/À) or both MTX and 5 mM dipyridamole (+/+) (a). The numbers represent the mean of three or four replicates per group ± s.d. Statistical analysis was performed to determine whether colony formation was reduced in the presence of MTX and DP. CSIIEG-CFC were significantly inhibited in the presence of MTX/DP, as compared with untreated CSIIEG-CFC (P ¼ 0.028). In panel b, drug-resistant colonies derived from DL2G-expressing cells that were formed in the presence and absence of selective conditions are shown ( Â 10 objective). Fluorescence images were captured at the same exposure (9 s) and then modified identically with Adobe Photoshop CS2 version 9 (brightness, À60; contrast: +35, smart sharpen). CFC, colony-forming cells; DP, dipyridamole; GFP, green fluorescent protein; hESC, human embryonic stem cell; MTX, methotrexate; MTXr, methotrexate resistant.
Expression of MTXr-DHFR in hESCs JL Gori et al Figure 5 Detection of hESC-derived progeny in the peripheral blood of recipient mice. After 10 days in co-culture with M2-10B4 stromal cells, EFDIG-hESC-derived hematopoietic cells were infused into DHFR-BMT mice (HDM group) or non-irradiated mice (LDM, PBS groups). One week after transplantation, mice were treated daily with PBS, 0.5 mg kg À1 (LDM) or 2 mg kg À1 (HDM) MTX for 4 weeks. GFP marking and circulation of human cells (as detected by staining with TRA-1-85 antibody) in the peripheral blood was evaluated by flow cytometry at 6 (a) and 12 (b) weeks post cell transplantation. Mean percentages for each group are shown (bars). GFP percentages were also normalized to the total GFP marking (20%) associated with the input EFDIG hESC-differentiated population. Levels of statistical significance: *Po0.05, **Po0.005 and ***Po0.0005. BMT, bone marrow transplanted; DHFR, dihydrofolate reductase; GFP, green fluorescent protein; HDM, highdose methotrexate; hESC, human embryonic stem cell; LDM, low-dose methotrexate; MTX, methotrexate; PBS, phosphate-buffered saline. 
Discussion
Our study is the first report of MTX-resistance-gene transfer to potentiate transplantation and selective engraftment of hESC-derived cells. We provide a model system to evaluate in vivo selection with antifolateresistance genes in hESC-hematopoietic cells that may be applied to evaluate other chemotherapeutic drug-resistance systems. In order to characterize the expression of Tyr22-DHFR in hESCs, we first achieved stable DHFR-GFP expression in hESCs using three different genetic configurations. In contrast to control CSIIEG-hESCs, GFP expression decreased over time in cells transduced with DHFR-GFP bicistronic lentiviral vectors, possibly due to epigenetic silencing. We then used MTX chemotherapy and DHFR expression to establish teratomas with increased MTX resistance that were also enriched for gene-modified cells, as determined by the fold increase in transgene copies in the teratoma, as compared with the GFP transgene copies detected in the undifferentiated input cell population. Finally, we demonstrated the feasibility of using Tyr22-DHFR and MTX chemotherapy to achieve in vivo selection and increased engraftment of hESC hematopoietic cells in immunodeficient mice. These results extend our previous work using lentivirusmediated chemoprotection in murine marrow-derived HSCs to demonstrate the effectiveness of this approach in ES-derived HSC and in the human system. Historically, in vivo selection at the level of slowly dividing stem cells has not been achieved by MTX administration alone, because the inhibitory activity of MTX affects primarily highly proliferative cells, such as myeloid and lymphoid progeny. In vivo selection has been achieved using the antifolate trimetrexate when administered along with nucleoside transport inhibitor. 14, 45, 46 Although trimetrexate/nitrobenzylmercaptopurine ribose phosphate treatment was sufficient to achieve in vivo selection of gene-modified HSCs in mice, selection was only transient in a study of non-human primates. 14, 45 In contrast to the DHFR/antifolate system, expression of P140K-O 6 -methylguanine DNA methyltransferase (P140K-MGMT), which confers resistance to O 6 -benzylguanine and alkylating agents such as 1,3-bis-(2-chloroethy)-1-nitrosourea (BCNU) and temozolomide, has been shown to support significant, long-term in vivo selective expansion of gene-modified HSCs in dogs. 7, 47 However, in a clinical study using retroviral vector to transduce MGMT activity in hematopoietic cells, the gene-transfer frequency remained low. 8 The differential outcomes between the antifolate studies and the MGMT studies highlight the importance of evaluating drugresistance genes and chemoprotection in alternative cell sources that can be expanded ex vivo, in order to anticipate potential challenges that may arise in future studies of large animals and humans.
Drug-resistance-gene therapy models of human-mouse xenografts have been developed to determine whether high-dose chemotherapy inhibits human tumor progression and to determine the extent of protection provided by drug-resistance genes (DHFR, MGMT) expressed in the mouse marrow. 48, 49 Human CD34 + cells, either from umbilical cord blood or mobilized peripheral blood have been evaluated in mice after transfer of P140K-MGMT. 50, 51 Pollok et al. 50 showed that O 6 -benzylguanine/BCNU treatment increased long-term engraftment of CD45 + GFP + cells in the marrow of NOD/SCID mice two-to eight fold 14 weeks after transplantation of umbilical cord blood or mobilized peripheral blood CD34 + cells, respectively. In Pollok's studies, CD34-enriched cell populations that were 60% GFP + were infused into mice that were irradiated immediately before transplantation. Four treatments of O 6benzylguanine and BCNU had a potent selective effect in vivo, increasing CD45 + cell engraftment in the BM from 30 to 80% for umbilical cord blood-derived cells and from 20 to 90% for mobilized peripheral blood-derived cells. These results demonstrate the potential effectiveness of in vivo human stem cell selection as xenografts in immunodeficient animals, also applicable to human ES cells as demonstrated in this article.
In our study, we transplanted an unselected population of mixed, differentiated cells that was only 20% GFP + at the time of infusion. By normalizing the GFP marking of engrafted cells to this initial percentage (that is, by dividing the percent of GFP + cell detected in the BM by the percent of GFP + cells in the input cell population), the selective effect of MTX treatment becomes even more apparent at 12 weeks post transplant (Supplementary Figure S3 ). Twelve times more GFP marking (6 versus 0.5% mean GFP + cells) was detected in the BM of HDM as compared with PBS-treated mice. In the peripheral blood, five times more GFP marking (22 versus 4% mean GFP + cells) was detected in HDMtreated mice versus PBS-treated mice. We thus achieved significantly higher long-term engraftment of hESC-hematopoietic cells in the BM of treated mice, compared with that in untreated mice. It is also striking that the levels of CD34 + /CD45 + cells were similar in the LDM and HDM treatment groups. These results demonstrate the long-term selective effects of MTX on hESC-hematopoietic cell engraftment and show that MTX supports in vivo selection that persists long after treatment cessation.
Induced pluripotent stem cells and/or hESC-derived hematopoietic cells provide candidate sources for allogeneic or autologous HSC transplantation; so it is important to consider the conditions of this clinical translation and the potential challenges that may arise in achieving effective engraftment of these cells after transplantation. Drug-resistance-gene transfer represents an important complement to such cell-based therapies as a means of supporting selective engraftment of genemodified cells for hematopoietic reconstitution and prevention of allograft rejection. In this study, we show that MTX administration provided a selective benefit to the engraftment of MTXr-DHFR hESC-hematopoietic cells in the BM of NSG mice. Other conditions may improve hematopoietic differentiation 26, 42, 52 coupled with the evaluation of more potent drug-resistance genes (such as MGMT) that also support stem cell selection will better define the potential roles of drug resistance genes in hESC-derived hematopoietic function in vivo.
Materials and methods
Embryonic stem cell culture
The hESC line H9 (WiCell Research Institute Inc., Madison, WI, USA) was maintained in mitotically Expression of MTXr-DHFR in hESCs JL Gori et al inactive mouse embryonic fibroblast feeder layers (Chemicon/Millipore, Temecula, CA, USA) that were irradiated at 5500 cGy using a cesium source as previously described. 17, 41 Mouse embryonic fibroblasts and the stromal cell line M2-10B4 were maintained as described. 17, 41 
Lentiviral vector construction and vector preparation
The self-inactivating, HIV-1-based lentiviral plasmids CCDG, CSIIMCS, CSIIEG, DL2G and EFDIG have been previously described. 12 Briefly, in these vectors the hEF-1a promoter regulates the transcription of the murine Tyr22-DHFR variant and enhanced GFP coding sequences. EFDIG contains a picornaviral internal ribosomal entry site, DL2G constitutes a genetic fusion between the two transgenes and CSIIEG encodes GFP alone. To construct REDPeG, the Tyr22-DHFR-coding sequence was amplified from pCCDG 12 using sense (5 0 -TCT CGAGGATTCTCTAGAGCAAGCTTTTA-3 0 ) and antisense (5 0 -GGCGGTACCGATAAGCTGATCCTCTA-3 0 ) primers (BamHI and KpnI sites underlined). The PCR product was cloned between the BamHI and KpnI sites in pRSCEMPGw2 (a construct identical to REDPeG containing a methylguanine DNA methyltransferase sequence at the site into which DHFR was inserted, kindly provided by Dr Hans-Peter Kiem, Fred Hutchinson Cancer Research Center, Seattle, Washington) to yield REDPeG, in which the hEF-1a promoter regulates transcription of Tyr22-DHFR, and the human phosphoglycerate kinase promoter regulates the expression of GFP. To construct the Tyr22-DHFR-expressing lentiviral vector plasmid CSIID, Tyr22-DHFR was excised from CCDG 12 and cloned into the EcoRI and BamHI sites of CSIIMCS. 40 Lentiviral vectors were packaged by DNAcalcium phosphate-mediated transfection of human HEK-293 cells, collected, concentrated and titered as previously described. 53 
Transduction of hESCs
Confluent hESCs growing on Matrigel (BD Biosciences, San Jose, CA, USA) were treated with 0.05% trypsin plus 2% chicken serum (Sigma-Aldrich, Saint Louis, MO, USA) for 7 min at 37 1C with or without a 1-h pretreatment with 10 mM Rho kinase (Rock) inhibitor Y-27632 (Calbiochem, EMD Biosciences, San Diego, CA, USA). Cells were collected by centrifugation and then suspended in transduction medium (conditioned medium described above, plus 8 ng ml À1 bFGF, 8 ng ml À1 polybrene, with or without 10 mM Rock inhibitor). One million cells (in small aggregates) were mixed with the lentiviral vector to achieve a multiplicity of infection of 2.5 (based on functional titer (DHFR or GFP transducing units per ml) on 3T3TK À fibroblasts) and replated on Matrigel. Cell suspensions were gently agitated every hour for 3 h to facilitate virus-cell contact. Twenty-four hours later, the cells were gently washed with Dulbecco's modified phosphate buffered saline (DPBS) and covered with fresh conditioned medium plus 8 ng ml À1 bFGF. Two weeks and two passages later, confluent transduced cell populations were subcultured at 2:1 onto mouse embryonic fibroblast feeders.
Karyotype analysis
The University of Minnesota Cytogenetics Core laboratory performed the karyotype analysis. Gene-modified, undifferentiated hESCs were cultured in six-well plates as described above. Cells in metaphase were evaluated by G-banding. For each gene-modified cell population, 20 metaphase cells were analyzed at a 400-475 band resolution.
MTXr-DHFR enzyme assay
Transduced, undifferentiated hESCs were collected by centrifugation and stored at -20 1C in DPBS. Cell extracts were prepared and protein content was determined as described. 12 Cell extracts were incubated with or without 0.25 mM MTX for 10 min. Addition of 120 mM NADPH (b-nicotinamide adenine dinucleotide phosphatereduced tetrasodium salt) and 20 mM dihydrofolate started the enzyme reaction. The change in absorbance (A 340 ) on a DU40 spectrophotometer (Beckman Coulter, Fullerton, CA, USA) was monitored and recorded after reaction initiation. One unit of enzyme activity is defined as the amount of enzyme required to reduce 1 nmol of dihydrofolate per minute (e ¼ 12 300 M À1 cm À1 ). 54 
Hematopoietic differentiation of hESCs
Undifferentiated hESCs were subcultured onto M210 cells in Rosewell Park Memorial Institute (RPMI) media with 15% fetal bovine serum (FBS) and allowed to differentiate as described. 41 Between days 7 and 35, wells were harvested every 3-7 days for flow cytometric analysis of phenotype and GFP expression. For colonyforming assays, differentiation co-cultures were collected 16-19 days after plating on M210 stromal cells. A total of 2.5 Â 10 5 cells were replated onto Methocult GF + medium (Stem Cell Technologies, Vancouver, BC, Canada) supplemented with or without 5 mM dipyridamole (Sigma-Aldrich) and 30 nM MTX. Hematopoietic colonies were scored 16 days later for computation of CFCs in the plated cell population.
Animals
NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice (The Jackson Laboratory, Bar Harbor, ME, USA) were bred and maintained in micro-isolator cages and provided with autoclaved food and water containing antibiotics ad libitum. All procedures were reviewed and approved by the University of Minnesota Institutional Animal Care and Use Committee.
BM transduction and transplantation in NSG mice
Bone marrow was flushed from the hind limbs of 8-to 12-week-old male NSG donor mice processed as described. 12 Cells were suspended in complete StemPro medium (Invitrogen, Carlsbad, CA, USA) supplemented with 2 mM L-glutamine (Gibco BRL, division of Invitrogen), 1% P/S, 8 mg ml À1 polybrene (Sigma-Aldrich) and cytokines (100 ng ml À1 each of human IL-3, IL-6 and mouse SCF (all from R&D Systems, Minneapolis, MN, USA)). 12 Lentivirus was added to cell suspensions to achieve a multiplicity of infection of 10 and incubated overnight in a humidified atmosphere containing 5% CO 2 in air at 37 1C. Eight-to twelve-week-old, syngeneic, female recipient mice were irradiated using a cesium source (320 cGy) and then intravenously infused with 2-3 Â 10 6 transduced marrow cells. Equal volumes of CSIIEGand EFDIG-hESC aggregates were injected intramuscularly into the right and left hind limbs, respectively, of untransplanted and CSIID marrow-transplanted NSG mice (transplant described in the preceding section). One month after cell aggregate injection, mice were treated 5-7 days per week with PBS or MTX, starting at 2 mg kg À1 day À1 on days 1-7 and then escalating to 4 mg kg À1 day À1 on days 8-30. Animals were euthanized and teratomas were excised, diameter measured and sections prepared for real-time qPCR, immunofluorescence or histopathological analysis.
Transplantation of hESC-derived hemato-endothelial cells in NSG mice
EFDIG-hESCs co-cultured with M2-10B4 stromal cells for 10 days were harvested by trypsinization as described above. A total of 4 Â 10 6 cells were injected intravenously into 8-to 12-week-old female NSG mice. In some cases, the mice were transplanted with CSIID-transduced BM 1-3 months (as described above) before hESC-derived cell transplantation. One week after hESC-hematopoietic cell infusion, animals were treated with PBS or MTX 5 days per week for 4 weeks (see section Results). Blood samples were taken 6 and 12 weeks after cell transplantation and analyzed by flow cytometry for GFP marking and human cell content.
Fluorescence microscopy, immunofluorescence and histopathology
Gene-modified hESCs were visualized using a Zeiss inverted fluorescence microscope (Axiovert 200M). Images were captured using a digital camera (Zeiss AxioCam) with the AxioVision version 4.6 software interface (all from Carl Zeiss MicroImaging GmbH, Mü nchen, Germany). Fluorescence images were captured ( Â 10-20 objective) at the same exposure and modified identically with Adobe Photoshop CS2 version 9. Fluorescence images of hematopoietic colonies were captured in a 9-s exposure time. Teratomas were embedded in optimal cutting temperature medium and frozen or fixed in 10% formalin. For immunofluorescence, teratomas were sectioned, fixed onto slides with 10% formalin and permeabilized with 0.25% Triton-X 100 in DPBS. Sections measuring 10 mm were incubated with 10% donkey serum to block nonspecific antibody binding and incubated with either 1:200 rabbit-anti-GFP in 10% donkey serum (Molecular Probes, Invitrogen) or rabbit isotype control antibody (Zymed, San Francisco, CA, USA) overnight at 4 1C. Slides were washed several times with DPBS, incubated for 1 h at room temperature with fluorescein isothiocyanate-conjugated donkey anti-rabbit secondary antibody (1:200 in 10% donkey serum), washed and set with Prolong gold antifade reagent plus DAPI (4,6-diamidino-2-phenylindole) (Invitrogen). Sections were visualized and images were captured ( Â 20 objective, 4 s exposure time) by fluorescence microscopy as described above. For histopathological analysis, formalin-fixed teratomas were embedded in paraffin, sectioned, mounted, stained with hematoxylin and eosin and analyzed by a veter-inary pathologist without prior knowledge of sample identity or treatment (MTX, PBS).
Real-time quantitative PCR
DNA was extracted from human teratomas or mouse tissue samples using the Puregene DNA purification system (Gentra Systems Inc., Minneapolis, MN, USA). DNA was quantitated spectrophotometrically (A 260 ) and qPCR reactions were performed as previously described without prior knowledge of sample identity or treatment (MTX, PBS).
Flow cytometry
Flow cytometric analysis of differentiating hESCs in stromal cell co-culture was performed as previously described. 17, 41 To assess the engraftment of hESC-derived progeny and gene marking in vivo, blood, BM and spleen were harvested from mice after killing and treated with ammonium chloride solution (Stem Cell Technologies). Liver was treated with collagenase mixture (1 mg ml À1 collagenase-IV, 50 mg ml À1 DNase-I (Gibco, Invitrogen), 10% FBS in RPMI media). Cells were resuspended in Iscove's modified DMEM plus 5% FBS (I-5) medium and layered onto Ficoll-Paque Plus (GE Healthcare Biosciences AB, Uppsala, Sweden). After centrifugation, the Ficoll layer was collected. Blood, BM and liver cells were suspended in I-5 medium, filtered, collected and incubated in blocking solution (5% human AB serum (Valley Biomedical, Winchester, VA, USA) 5% FBS in DPBS) for 30 min on ice. Cells stained with phycoerythrin-conjugated TRA-1-85 (R&D Systems) were also treated with 4 mg of human IgG1 protein (R&D Systems) for 15 min at room temperature. Cells were suspended in the flow cytometry buffer (0.1% NaN 3 , 2% FBS in DPBS) and stained with pairs of APC-and phycoerythrinconjugated mouse anti-human antibodies for 20 min at 4 1C in the dark. Cells were suspended in buffer plus 2 mg ml À1 7-amino actinomycin-D (7-AAD; Sigma-Aldrich).
All flow cytometry data were collected using a FACSCalibur Instrument with the CellQuest Pro software interface (BD Biosciences). Depending on the cell or tissue sample, 5000-20 000 live events (7-AAD-negative gate) were collected for analysis. Data were analyzed using FlowJo software, version 8.6.1. (Tree Star Inc., Ashland, OR, USA). All antibodies were obtained from BD Pharmingen (San Diego, CA, USA) except phycoerythrin-conjugated Flk-1, TRA-1-85 (both from R&D Systems) and CD235A (GlyA) (from Becton Coulter, Fullerton, CA, USA).
Statistical analysis
To test for differences among treatment groups or genemodified cell populations, data were evaluated using an unpaired, two-tailed student t-test in Microsoft Excel, version 11.5. Differences were considered statistically significant if P-values were less than 0.05.
